Senti Biosciences (NASDAQ:SNTI) Stock Price Down 3.2% – What’s Next?

Senti Biosciences, Inc. (NASDAQ:SNTI) shares traded down 3.2% on Thursday . The stock traded as low as $0.4203 and last traded at $0.4266. Approximately 117,052 shares were traded during mid-day trading, a decline of 67% from the average session volume of 356,246 shares. The stock had previously closed at $0.4405.

Wall Street Analyst Weigh In

SNTI has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Friday, July 17th. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Chardan Capital boosted their price objective on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Senti Biosciences Trading Down 3.2%

The firm has a market cap of $13.29 million, a price-to-earnings ratio of -0.22 and a beta of 2.04. The firm has a 50-day moving average of $0.92 and a two-hundred day moving average of $0.95.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.22. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. As a group, equities analysts anticipate that Senti Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Investors Weigh In On Senti Biosciences

Several hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Senti Biosciences in the fourth quarter valued at approximately $40,000. Virtu Financial LLC bought a new position in Senti Biosciences during the fourth quarter worth $46,000. Citadel Advisors LLC bought a new position in Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC raised its stake in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Senti Biosciences during the 2nd quarter valued at $1,883,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.